(RTTNews) - While reporting financial results for the fourth quarter on Thursday, Bristol-Myers Squibb Co. (BMY) initiated its adjusted earnings and revenue growth guidance for the full-year 2025.

Bristol Myers Squibb said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost-savings effort to chart a path toward long-term growth. The company also issued full ...

Pharma giant Bristol Myers Squibb is planning another round of cost cutting as part of a broader restructuring plan. Under the “strategic productivity initiative” announced Feb. 6, the ...

As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company has launched another round of layoffs in its home state of New Jersey. BMS’ latest workforce reduction affects ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other stocks. Jim Cramer, the host of Mad Money, discussed the upcoming market and ...

Ratings for Bristol-Myers Squibb BMY were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ...

Analyst Terence Flynn of Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of $39.00. Terence Flynn’s rating is based on ...

David Risinger’s rating is based on the impressive launch performance of Bristol-Myers Squibb’s Cobenfy, which is showing strong sales momentum since its introduction for schizophrenia treatment.

In recent trading, shares of Bristol Myers Squibb Co. (Symbol: BMY) have crossed above the average analyst 12-month target price of $59.62, changing hands for $59.67/share. When a stock reaches ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...